<DOC>
	<DOCNO>NCT00462982</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sunitinib work treat patient brain metastasis cause kidney cancer melanoma .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Brain Metastases Caused Kidney Cancer Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy sunitinib malate , term objective radiographic response brain lesion , patient brain metastasis secondary renal cell carcinoma melanoma . Secondary - Determine overall progression-free survival . OUTLINE : Patients receive oral sunitinib malate daily day 1-28 . Courses repeat every 6 week 1 year absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma renal cell carcinoma Metastatic brain disease Must assessable target intracranial lesion ( ) , define measurable disease ≥ 10 mm long diameter appropriate stereotactic radiosurgery surgical resection Lesions previously treat radiosurgery AND eligible resection use target lesion true tumor progression baseline scan ( i.e. , ≥ 20 % increase long diameter lesion ) rather radionecrosis True progression must confirm PET scan corroborate image use distinguish radionecrosis No leptomeningeal metastases primary dural metastasis PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 60100 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Total leukocyte count ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 2.0 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Hemoglobin ≥ 9.0 g/dL Calcium ≤ 12.0 mg/dL AST ALT ≤ 1.5 time ULN PT ≤ 1.5 time ULN No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No uncontrolled medical illness include , limited , follow : Hypertension ( i.e. , blood pressure &gt; 150/100 mm Hg ) Thyroid disease Severe valvular disease Severe pulmonary disease HIV/AIDS Severe psychiatric illness No cardiac dysrhythmia ≥ grade 2 No prolong QTc interval baseline EKG No systemic hemorrhage ≥ grade 2 within past 4 week No CNS hemorrhage ≥ grade 2 Grade 1 ( asymptomatic ) CNS hemorrhage allow investigator 's discretion None follow within past 6 month : Myocardial infarction Unstable angina Symptomatic congestive heart failure Stroke/transient ischemic attack Pulmonary embolism Ejection fraction ≥ 50 % baseline echocardiogram OR &lt; 20 % decrease ejection fraction prior study PRIOR CONCURRENT THERAPY : No prior multitargeted tyrosine kinase inhibitor therapy ( e.g. , sunitinib malate sorafenib ) No coronary/peripheral arterial bypass surgery within past 6 month More 4 week since prior surgery recover More 4 week since prior concurrent experimental therapy cytotoxic chemotherapy More 4 week since prior immunotherapy More 2 week since prior stereotactic radiosurgery recover More 7 day since prior concurrent drug interact CYP3A4 family , include enzymeinducing antiepileptic drug , warfarin , Hypericum perforatum extract ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>